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ABSTRACT 
K-Ras serves as an important component of signalling pathways involved in cell cycle control. 
Proper functioning K-Ras is regulated by phosphodiesterase δ (PDEδ). Deltarasin binds to this 
prenyl-binding protein thus inhibiting its interaction with K-Ras and hence disrupting Ras 
signalling.
 
The objective of this study is to use Deltarasin as a template for further iteration of the 
design of novel drugs with potential clinical use in the management of malignancies.
 
Deltarasin 
was constructed using SYBYL-X
®
 V1.2, followed by analysis of the critical interactions with the 
amino acids lining the Ligand Binding Pocket (LBP). Seeds were modelled based on the 
Deltarasin scaffold and Virtual Screening (VS) was used to identify ‘hits’, using the same 
molecule as a template.
 
SYBYL-X
®
, X-SCORE
®
, LigBuilder
®
, Visual Molecular Dynamics 
(VMD), Accelrys
®
 Draw, Accelrys
®
 Discovery Studio v3.5, Protein Data Bank and 
ZINCPharmer
®
 were all used to generate results. The main outcome measures of this research 
project are to discover and optimise in silico high binding affinity of PDEδ inhibitory drug 
molecules, as well as molecule display, Ligand Binding Affinity (LBA) and Ligand Binding 
Energy (LBE) calculations, seed generation and ultimately de novo design.
 
Based on reviewed 
SAR studies, nine seeds were generated using SYBYL-X
®
 V1.2. The POCKET and GROW 
algorithm of LigBuilder
®
 V1.2 were used to generate in silico molecules for each seed.
 
Surflex-
docking in SYBYL-X
®
 V1.2 resulted in five molecules with a total docking score of six or 
greater.
 
De novo molecules created and optimized, present viable leads for high-throughput 
screening, leading to identification of novel PDEδ inhibitors for use as anti-cancer agents. 
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INTRODUCTION 
K-Ras forms part of the Ras family of proteins which serve as important components of 
signalling pathways involved in cell cycle control, cell adhesion, endocytosis, exocytosis and 
apoptosis. Proper functioning of this protein is regulated by the prenyl-binding protein 
phosphodiesteraseδ (PDEδ), which facilitates its diffusion through the cytoplasm. If K-Ras is 
successfully inhibited, it can no longer bind to this transport protein and hence cannot function 
properly.
1
  
Although a variety of genetic modifications have been identified in pancreatic carcinoma, 
mutations of K-ras are by far the most commonly occurring mutation. Mutations are seen in over 
85% of pancreatic ductal carcinomas. The development of mutations in K-ras appear early in the 
development of pancreatic cancer, having been observed in precursor lesions within the 
pancreatic duct. The mutations in K-ras in pancreatic cancer are also unique in that it typically 
involves codon 12, but may also rarely involve codons 13 or 61.
2
 These mutations in K-Ras 
make it resistant to GAP and as a result lead to constitutive activation of downstream pathways, 
resulting in altered regulation of cellular proliferation. 
Based on the frequency and apparent critical role of K-Ras in pancreatic cancer, several 
approaches have been developed to indirectly block the functioning of K-Ras. High throughput 
screening has been performed to identify small molecules that bind to the farnesyl-binding 
pocket of PDEδ. This yielded several benzimidazole hits. Crystal structure analysis of these 
compounds in complex with PDEδ revealed that two benzimidazoles bind to the hydrophobic 
pocket of the prenyl-binding pocket. One molecule is deeply buried and overlaps with the 
farnesyl-binding site. The second molecule is located close to the binding site that makes main 
chain contacts with two carboxy-terminal RHEB (Ras homologue enriched in brain) amino 
acids. Binding of the inhibitors is mediated by hydrophobic interactions and hydrogen bonding 
between the benzimidazole units and Tyr
149
and Arg
61.
 
3
  
Thus far, the most effective inhibitor of PDEδ is Deltarasin, as it has proven to sharply reduce 
tumour growth in mice. Deltarasin is a small molecule that binds to the farnesyl-binding pocket 
of PDEδ (Kd=41 nM) in cells thus inhibiting its interaction with K-Ras and hence disrupting Ras 
signalling. 
This study aims to use the Deltarasin molecule as a scaffold for further iterative design of de 
novo molecules capable of inhibiting PDEδ with the possibility of yielding molecules with 
increased binding affinity to the receptor, improved pharmacokinetic properties and satisfactory 
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bioavailability. 
 
Figure 1: Deltarasin bound to PDEδ rendered in UCSF Chimera® V1.11.2 1 
PDB Entry – 4JVB 2 
MATERIALS AND METHOD  
Using the Protein Data Bank, the crystallographic deposition with the best resolution that 
described the bound coordinates of PDEδ with a small molecule (rac-2) was selected. 4 This was 
PDB entry 4JVB, with a resolution of 1.75Å. 
5
 
Each deposition was visualized and edited in SYBYL-X
®
 v1.2
6
 molecular modelling software, 
prior to Ligand Binding Affinity (LBA) estimation. Water molecules at a distance ≥ 5Å from the 
LBP were deleted. At the end of the process, a file saved in .mol2 format containing the bound 
coordinates of the extracted small molecules and another file saved in .pdb format containing the 
apo receptor, without the deleted water molecules, were generated.   
Two different approaches were adopted in this research project; Virtual Screening (VS) and de 
novo drug design. 
Approach 1 – Virtual Screening  
This first approach is a drug discovery process used to quickly assay the biological or 
biochemical activity of a large number of drug-like compounds to identify ‘hits’.  
Following conformational analysis, the optimal conformer of Deltarasin was chosen. 
ZincPharmer
®
, 
7
 the online molecular database which rapidly screens over 2 million compounds, 
was used to extract small molecules predicted to have a similar shape and electrostatic 
compositions to the template molecule Deltarasin.  
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A protomol was generated using SYBYL-X
®
 v1.2
6
. This is intended to mimic the ideal 
interactions made by a perfect ligand to the protein active site. Next, the original PDB file 
(4JVB)
5
 was retrieved from the RCSB server through SYBYL-X
®
 v1.2
6
. The ligand was 
extracted from the protein backbone, while the water molecules together with any other ions 
deemed inessential for ligand stability were removed from the protein. To generate the protomol, 
the active site was used as placement for the Surflex-Dock process. 
The molecules that were identified from ZincPharmer
®
 
7 
during the VS process in .pdb format, 
were converged into a single .sdf format file using MONA 
8
, an interactive tool that has been 
designed to prepare and visualize large small molecule datasets. The molecules were filtered 
using Lipinski’s Rules 9 as inclusive criteria. This means that all generated molecules with 
molecular weight less than 500, LogP less than 5 and Hydrogen-Bond donors and acceptors less 
than 5 and 10 respectively were retained on the premise that they would be orally bioavailable. 
The .sdf files prepared were chosen as Ligand Sources and the Surflex Dock process was run in 
SYBYL-X
®
 v1.2.
6
 
Approach 2 – de novo drug design 
For this approach, the extracted ligand molecules in .mol2 format and their respective protein 
binding pocket .pdb files from the first approach, were transferred to X-Score
®
 v1.3 
10 
, which 
runs on a Linux Platform. The X-Score
®
 v1.3
10
 algorithm was used to measure the LBA (in pKd) 
of Deltarasin for its cognate receptor. This process was done to establish a baseline affinity 
against which the LBAs of other seeds would then be compared. 
A thorough study of the Structure-Activity Relationship (SAR) for Deltarasin bound to PDEδ 
was carried out. Discovery Studio v3.5 
11 
was used to generate 2D topology maps with the scope 
of facilitating SAR understanding. All crucial bonds and interactions were retained when 
creating seeds. Conversely, moieties which were deemed not important for binding to the Ligand 
Binding Pocket (LBP) were removed and growing sites were created in their place. Four 
successful seed structures were created based on the acquired SAR. 
De novo design was carried out using LigBuilder
®
 v1.2.
10 
The POCKET module was used to 
identify the pharmacophoric structural features and key interaction sites that a hypothetical 
ligand for a given LBP could occupy. In this study, Deltarasin was used to probe the cognate 
receptor in .pdb file format according to the POCKET algorithm. The resulting data was then 
used by the GROW module in LigBuilder
®
 v1.2
10
 through which de novo design was performed. 
This module constructs ligand molecules for a target protein, in this case PDEδ, by applying the 
inbuilt growing strategy algorithm. Seeds were allowed to grow alternative side chains. An 
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assessment to predict the drug-likeness for the de novo ligands was carried out based on the 
parameters of Lipinski’s Rules by transferring each generated de novo ligand to Discovery 
Studio v3.5,
11
 which determined Lipinski-Rule-compliance of such novel ligands.  
RESULTS AND DISCUSSION 
Approach 1 
The Surflex Dock Process resulted in a number Lipinski Rule compliant molecules. The top five 
ligands with the highest Total Score are shown in Table 1 below. 
Table 1: Top 5 ligand molecules with the highest Total Score 
Molecule ID 3D Structure LBA (pKd) LBE (kcalmol
-1
) 
ZINC05921075  6.82 57.99 
ZINC17160093  6.87 116.07 
ZINC08438548  7.15 83.20 
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ZINC08430796 
 
6.72 90.48 
ZINC08426403 
 
6.9 57.69 
A graph of LBA and LBE vs Molecule Number was plotted for these ligands generated (Graph 
1) and the molecule found to have the highest LBA and lowest LBE was ZINC08426403, having 
an LBA of 6.9. 
 
Graph 1: LBA (pKd) and LBE (Kcalmol
-1
) vs Molecule Number 
Approach 2 
The baseline affinity of Deltarasin for the PDEδ receptor was calculated (in pKd) using X-
Score® v1.3 and was found to be 6.67. 
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Ten seeds were created using SYBYL-X
®
 v1.2,
6
 four of which showed successful growth. The 
number of Families, Lipinski-Rule compliant molecules and Highest pKd can be seen in Table 2 
below. A total of 346 Lipinski-Rule compliant molecules were generated by this method. 
Table 2: Number of Lipinski-Rule compliant molecules from each seed 
Seed Number Number of 
Families 
Number of 
Lipinski-Rule 
compliant 
molecules 
Highest pKd 
1 3 9 9.83 
2 17 94 9.96 
3 15 90 9.97 
4 9 153 9.97 
Two molecules were identified as having the highest binding scores across all families generated 
from the four different seeds. Seed 3 generated a molecule of molecular weight 374 and a 
partition coefficient of 4.92 whilst seed 4 yielded a molecule with an equally high pKd of 9.97, a 
molecular weight of 435 and a LogP of 4.81. 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUS
SION 
Figure 1: Molecules with the highest binding scores generated from seeds 3 and 4 
respectively. 
ZINC08426403, generated through the Surflex Dock process, was further analysed relative to the 
established SAR of Deltarasin to its cognate receptor and through 2D and 3D topology maps, it 
pKd = 9.97 
mol. weight = 374 Da 
LogP = 4.92 
pKd = 9.97 
mol. weight = 435 Da 
LogP = 4.81 
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was concluded that the two phenyl groups are crucial in the binding of inhibitor molecules to the 
active site. These lipophilic groups extend into the active site of PDEδ and occupy hydrophobic 
pockets. This explains why the generated de novo structures which did not include these highly 
lipophilic groups had a much lower binding affinity. In fact, the molecules yielded from the 
second approach, having the highest binding scores also possess highly lipophilic groups which 
fit comfortably into the highly hydrophobic pockets in the active site.  
The de novo structures generated by this approach all had a molecular weight and LogP that was 
significantly lower than that of the parent molecule Deltarasin, potentially leading to better 
bioavailability and ultimately more effective treatment for the patient.  
Limitations 
As with any in silico drug design study, this project was conducted using a static, rigid LBP, 
which is very different from in vivo modeling and may thus yield different results. This was the 
major limitation of the freeware used. 
CONCLUSION 
In conclusion, in silico calculated high affinity and improved Lipinski-Rule compliance, make a 
case for synthesis of the optimal generated molecules. The ability of these molecules to 
successfully modulate the PDEδ transport protein could then be further validated through 
molecular dynamic studies and in vitro assays. 
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